Drug Trial Radar · NCT05353361
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
402
Planned (sponsor's estimate)
Start
May 23, 2022
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.
Conditions
- Breast Cancer
Interventions
SHR-A1811:PyrotinibDrug
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib:Tablet, 160mg / tablet, 80mg / tablet, oral
SHR-A1811;PertuzumabDrug
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab:Injection, 420 Mg (14 ml) / bottle, intravenous drip
SHR-A1811;AdebrelimabDrug
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab:Injection, 12ml: 0.6g/bottle, intravenous drip
SHR-A1811;Albumin paclitaxelDrug
SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel:Injection, 100mg / box, intravenous drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT(Phase I (dose exploration phase) )Time frame: 21 days after the first administration of each subject
- AE(Phase I (dose exploration phase) )Time frame: from Day1 to 40 or 90 days after last dose
- Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) )Time frame: from Day1 to 40 or 90 days after last dose
- Objective response rate(Phase II (efficacy expansion phase))Time frame: Two years after the last subject was enrolled in the group
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.